| ESVC – European Society of Veterinary Cardiology |
| Thursday 21 September |
| ESVC-O-1 |
09.00-09.15 |
Grosso |
Echocardiographic evaluation of main pulmonary artery and right pulmonary artery size in dogs with pulmonary hypertension |
| ESVC-O-2 |
09.15-09.30 |
Phetariyawong |
Left ventricular myocardial protein profile in dogs with myxomatous mitral valve disease and dilated cardiomyopathy |
| ESVC-O-17 |
09.30-09.45 |
Vezzosi |
The Mitral INsufficiency Echocardiographic (MINE) score in dogs with preclinical myxomatous mitral valve disease |
| ESVC-O-5 |
10.00-10.15 |
Sleeper |
Gene Therapy for the Treatment of Doberman Dilated Cardiomyopathy |
| ESVC-O-6 |
10.15-10.30 |
Carter |
Combined physical examination variables and N-terminal pro-brain natriuretic peptide in predicting cardiac disease in asymptomatic cats with murmurs |
| ESVC-O-7 |
11.20-11.35 |
Edgerton |
Investigation of the indications for and outcome of ambulatory electrocardiography in a referral population of dogs. |
| ESVC-O-8 |
11.35-11.50 |
Cala |
Transvenous closure of patent ductus arteriosus (PDA) with Nit-Occlud® occlusion system in nine dogs and one cat with a body weight less than 3 kg |
| ESVC-O-9 |
11.50-12.05 |
Liu |
Tetranectin as a Potential Biomarker for Feline Hypertrophic Cardiomyopathy |
| ESVC-O-10 |
12.05-12.20 |
Pierce |
Evaluation of the circulating renin-angiotensin-aldosterone system in healthy young dogs and dogs with right-sided congenital heart disease |
| ESVC-O-11 |
12.20-12.35 |
Escalda |
Assessment of heart rate in dogs with atrial fibrillation: Are two days better than one? |
| ESVC-O-12 |
12.35-12.50 |
Rogg |
Prevalence and progression of azotemia during treatment of congestive heart failure in cats |
| Friday 22 September |
| ESVC-O-13 |
14.25-14.40 |
Romito |
Clinical efficacy and tolerability of oral amiodarone and sotalol in dogs with tachyarrhythmias |
| ESVC-O-14 |
14.40-14.55 |
Goodrich |
Incidence of restenosis and associated risk factors in dogs undergoing balloon valvuloplasty for pulmonic stenosis |
| ESVC-O-15 |
14.55-15.10 |
Szatmari |
Do practicing veterinarians follow the ACVIM consensus guidelines for staging myxomatous mitral valve degeneration in dogs? |
| ESVC-O-16 |
15.10-15.25 |
Chang |
The Pulmonary hypertension Remodeling/hemodynamic-Induced Manifestations on Echocardiography (PRIME) score for predicting the severity of canine pulmonary hypertension |
| ESVC-O-3 |
15.25-15.40 |
Reimann |
Renin-angiotensin-aldosterone and phosphodiesterase system gene polymorphisms associated with congestive heart failure in Cavalier King Charles Spaniels with myxomatous mitral valve disease |
| ESVC-O-18 |
15.40-15.55 |
Wong |
Left atrial rupture secondary to myxomatous mitral valve disease in 33 dogs (2017-2022) |
| ESVC-O-19 |
16.30-16.45 |
Van de Watering |
Ultrasonographic assessment of abdominal aortic flow to evaluate hemodynamic significance of left-to-right shunting patent ductus arteriosus in dogs |
| ESVC-O-20 |
16.45-17.00 |
McLaughlin |
Timing and patterns of resolution of lung ultrasound B-lines compared to lung auscultation and respiratory rates in hospitalized dogs with cardiogenic pulmonary edema |
| ESVC-O-21 |
17.00-17.15 |
Climent-Pastor |
Use of intravenous nitroglycerin in the treatment of acute left-sided congestive heart failure in dogs and cats |
| ESVC-O-22 |
17.15-17.30 |
Szatmari |
How confident are practicing veterinarians in recognizing, and differentiating pathologic from innocent murmurs in puppies? |
| ESVC-O-23 |
17.30-17.45 |
Kramer |
Implantation of a novel transcatheter mitral valve in a pig heart model. |
| ESVC-O-24 |
17.45-18.00 |
Boz |
End-diastolic forward flow and restrictive physiology in dogs with pulmonary stenosis |
| SCH – Society of Comparative Hepatology |
| Thursday 21 September |
| SCH-O-1 |
09.15-09.30 |
Proksch |
Cobalamin status derangements in dogs with portosystemic shunt |
| SCH-O-2 |
09.30-09.45 |
Da Silva |
Association between hyperlipidaemia and selected cholestatic markers in 75 dogs with suspect acute pancreatitis |
| SCH-O-3 |
09.45-10.00 |
Palizzotto |
Hepatic AA amyloidosis in shelter cats: clinico-pathological data and light microscopic findings |
| SCH-O-4 |
10.00-10.15 |
BEDEL |
Prevalence of canine cholangitis/cholangiohepatitis, a retrospective study based on 263 liver biopsy cases (2013-2021) |
| SCH-O-5 |
10.15-10.30 |
Dröes |
Point-of-care viscoelastometric evaluation of dogs with chronic hepatitis |
| ESVCP – European Society of Veterinary Clinical Pathology |
| Thursday 21 September |
| ESVCP-O-1 |
14.25-14.40 |
Frizzo Ramos |
Assessment of iron homeostasis and correlation of iron related parameters in healthy dogs |
| ESVCP-O-2 |
14.40-14.55 |
Mazzei |
Pleural effusion total nucleated cell count (TNCCpe), lactate dehydrogenase (LDHpe), total protein (TPpe) and their serum ratio (LDHratio and TPratio) in feline pleural fluids |
| ESVCP-O-3 |
14.55-15.10 |
Mazzei |
Discriminating transudates and exudates in cats with pleural effusion: comparison of diagnostic utility of Light’s criteria, simplified Light’s criteria and two traditional veterinary classification based on pleural effusion total protein (TPpe) and total nucleated cell count (TNCCpe) |
| ESVCP-O-4 |
15.10-15.25 |
Aroch |
The utility of feline serum amyloid a measured by immunoturbidimetry for diagnosing acute pancreatitis in cats |
| ESVCP-O-5 |
15.25-15.40 |
Zoia |
Evaluation of new strategies to classify canine pleural effusion |
| ESVCP-O-6 |
15.40-15.55 |
Zoia |
Diagnostic values of amylase, adenosine deaminase and acute phase proteins in canine pleural exudates |
| ESVCP-O-7 |
15.55-16.10 |
Cervone |
Lipiduria in dogs and cats: an incidental or pathological finding? |
| ESVCP-O-8 |
16.10-16.25 |
Molnár |
Development of a simple IFN-γ release whole blood assay for the assessment of Leishmania infantum specific cellular immunity in dogs |
| ESVCP-O-9 |
16.25-16.40 |
Proksch |
Reference intervals for evaluation of cobalamin status instead of sole cobalamin concentration in healthy dogs |
| ESVNU – European Society of Veterinary Nephrology and Urology |
| Thursday 21 September |
| ESVNU-O-1 |
09.00-09.15 |
Tang |
Risk factors and short-term implications associated with macroscopic nephrocalcinosis in cats with chronic kidney disease |
| ESVNU-O-2 |
09.15-09.30 |
Tang |
Pilot study evaluating the detection of nephrocalcinosis using ultrasonography in cats with chronic kidney disease |
| ESVNU-O-3 |
09.30-09.45 |
Pantaleo |
Evaluation of urinary podocin and nephrin as markers of podocyturia in dogs with leishmaniosis |
| ESVNU-O-4 |
09.45-10.00 |
Pantaleo |
Evaluation of urinary amylase to creatinine ratio as a marker of renal damage in dogs with leishmaniosis undergoing conventional anti-Leishmania treatment |
| ESVNU-O-5 |
10.00-10.15 |
Jiwaganont |
Analysis of serum proteomic in cats with polycystic kidney disease-1 gene mutation |
| ESVNU-O-6 |
10.15-10.30 |
Bennett |
Progression of chronic kidney disease in cats following subcutaneous ureteral bypass device placement for ureteral obstruction compared to cats with idiopathic chronic kidney disease |
| ESVNU-O-7 |
11.20-11.35 |
Mourou |
Subcutaneous ureteral bypass placement is associated with a high complication rate but a prolonged survival in cats: a retrospective study of 94 cases (2014 – 2021) |
| ESVNU-O-8 |
11.35-11.50 |
Hardy |
‘Interpretating discordant symmetric dimethylarginine and creatinine concentrations in relation to glomerular filtration rate |
| ESVNU-O-9 |
11.50-12.05 |
Hawes |
The neutrophil-to-lymphocyte ratio (NLR) in cats with chronic kidney disease (CKD) |
| Friday 22 September |
| ESVNU-O-10 |
09.00-09.15 |
Biscop |
Diagnostic value of cell cycle arrest biomarkers, tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), to identify dogs with acute kidney injury |
| ESVNU-O-11 |
09.15-09.30 |
Biscop |
Diagnostic value of urinary to serum neutrophil gelatinase-associated lipocalin (NGAL) ratio and fractional excretion of NGAL to differentiate dogs with acute kidney injury from healthy dogs, dogs with chronic kidney disease and critically ill dogs |
| ESVNU-O-12 |
09.30-09.45 |
Tagliasacchi |
Urinary neutrophil gelatinase-associated lipocalin (NGAL): A rapid lateral flow test in canine practice |
| ESVNU-O-13 |
09.45-10.00 |
Pichard |
Validation of a three-dimensional ultrasound device for non-invasive bladder volume measurement in dogs and cats |
| ESVNU-O-14 |
10.00-10.15 |
Pichard |
Genitourinary dysplasia in dogs and cats: A case series |
| ESVNU-O-15 |
10.15-10.30 |
Tang |
ACVIM Award Winning abstract: A Pilot Study to Identify Plasma Calciprotein Particles in Cats with Chronic Kidney Disease |
| ESCG – European Society of Comparative Gastroenterology |
| Friday 22 September |
| ESCG-O-1 |
09.00-09.15 |
Sung |
Fecal abundance of Prevotella copri, Ruminococcus gnavus, and Genus Collinsella in cats with chronic enteropathy |
| ESCG-O-2 |
09.15-09.30 |
Giordano |
Intestinal microbiota and fecal concentrations of fatty acids, sterols, and bile acids in cats with chronic enteropathy |
| ESCG-O-3 |
09.30-09.45 |
Lyngby |
Association of serum and fecal microRNA profiles in healthy cats and cats with gastrointestinal cancer or chronic inflammatory enteropathy |
| ESCG-O-4 |
09.45-10.00 |
Simpson |
Serum metabolomic analysis of dogs with chronic enteropathies |
| ESCG-O-5 |
10.00-10.15 |
Cagnasso |
Investigation of fecal microbiome and metabolome perturbations in dogs with protein-losing enteropathy |
| ESCG-O-6 |
10.15-10.30 |
Vecchiato |
Fecal microbial transplantation effect on clinical outcome and fecal microbiota and metabolome in dogs with chronic enteropathy refractory to diet |
| ESCG-O-7 |
11.20-11.35 |
Huber |
Plasma proteome signatures of canine acute haemorrhagic diarrhoea syndrome (AHDS) |
| ESCG-O-8 |
11.35-11.50 |
Pilla |
Combined omeprazole and carprofen induced fecal dysbiosis and decreased short-chain fatty acid production in healthy dogs |
| ESCG-O-9 |
11.50-12.05 |
Siegrist |
Functional cobalamin deficiency (normal cobalamin with increased methylmalonic acid concentration) is uncommon in dogs. |
| ESCG-O-10 |
12.05-12.20 |
Tolbert |
Intestinal lymphangiectasia is a common finding in healthy soft-coated wheaten terriers |
| ESCG-O-11 |
12.20-12.35 |
Stavroulaki |
Early-life antibiotic exposure and susceptibility to chronic diarrhea during adulthood in cats. |
| ESCG-O-12 |
12.35-12.50 |
Remmel |
Congenital partial colonic agenesis in cats: clinical, biological, diagnostic imaging, endoscopic and histopathologic characterization. A retrospective study of 17 cases. |
| ESVIM – European Society of Veterinary Internal Medicine |
| Saturday 23 September |
| ESVIM-O-1 |
14.25-14.40 |
Bailey |
Do dogs with either immune-mediated polyarthritis or steroid-responsive meningitis arteritis differ in their presentation and response to treatment compared to dogs with both diseases? |
| ESVIM-O-2 |
14.40-14.55 |
Bergum Hjellegjerde |
Utility of screening diagnostic imaging in identifying potential triggers of associative immune-mediated polyarthritis (IMPA) in dogs. |
| ESVIM-O-3 |
14.55-15.10 |
Shalvey |
Evaluation of the Utility of Haematological Ratios as Biomarkers in Dogs with Forebrain Disease |
| ESVIM-O-4 |
15.10-15.25 |
Leynaud |
Epidemiological and hematological variables are useful to specify the underlying disease processes associated with feline non-regenerative anemia: a retrospective study of 440 cases (2018-2022) |
| ESVIM-O-5 |
15.25-15.40 |
Rösch |
Pharmacokinetics of orally administered immunosuppressive dosage of cyclosporine A over 10 days in healthy cats |
| ESVIM-O-6 |
15.40-15.55 |
Knies |
Prevalence of persistent hypertension and situational hypertension in a population of elderly cats in The Netherlands |
| ESVIM-O-7 |
16.30-16.45 |
Mochel |
A Non-Invasive Model of Preclinical Metabolic Syndrome to Study the Effects of Sodium Glucose Transporter-2 Inhibitors in Dogs |
| ESVIM-O-8 |
16.45-17.00 |
Niinikoski |
Assessment of risk factors for sleep-disordered breathing in dogs |
| ESVIM-O-9 |
17.00-17.15 |
Langton |
The comparison of sinonasal clotrimazole distribution using trephination or catheterisation in a cadaver study |
| ESVIM-O-10 |
17.15-17.30 |
Fastrès |
Lung microbiota assessment in dogs with bronchomalacia |
| ESVIM-O-11 |
17.30-17.45 |
Jaffey |
Clinical performance of a point-of-care Coccidioides antibody test to diagnose pulmonary coccidioidomycosis in dogs |
| ESVIM-O-12 |
17.45-18.00 |
Rizzoli |
Generation of a comprehensive molecular cell atlas of the healthy canine lung. |
| ISCAID - International Society for Companion Animal Infectious Diseases |
| Friday 22 September |
| ISCAID-O-1 |
08.00-08.15 |
Museux |
Update on the distribution and seasonal occurrence of vector-borne diseases in dogs in France |
| ISCAID-O-2 |
08.15-08.30 |
Elgueta |
Seropositivity to the louping ill flavivirus in dogs in the United Kingdom |
| ISCAID-O-3 |
08.30-08.45 |
Strobl |
Comparison of prognostic factors in feline panleukopenia in juvenile and adult cats |
| ISCAID-O-4 |
14.25-14.40 |
Weidinger |
Comparison of antibody response after feline panleukopenia virus vaccination in kittens with and without gastrointestinal parasitic infection |
| ISCAID-O-5 |
14.40-14.55 |
Evason |
Performance of a molecular diagnostic as compared to routine centrifugal-flotation for fecal gastrointestinal parasite identification |
| ISCAID-O-7 |
15.10-15.25 |
Murillo |
Leishmania infantum-specific production of IL-2 in stimulated blood in dogs with different states of infection |
| ISCAID-O-9 |
15.25-15.40 |
Fernández |
Severe babesiosis in recently splenectomised dogs due to suspected or confirmed Babesia vulpes infection |
| ISCAID-O-10 |
16.30-16.45 |
Almendros |
Molecular detection of Babesia spp. in community and privately-owned cats in Hong Kong |
| ISCAID-O-11 |
16.45-17.00 |
Wenderlein |
Detection of pathogenic Leptospira spp. serogroups in Europe between 2017 and 2020 applying a gene-based molecular approach |
| ISCAID-O-12 |
17.00-17.15 |
Griebsch |
Serological evidence of exposure to Leptospira in dogs in Sydney, New South Wales, Australia |
| ISCAID-O-13 |
17.15-17.30 |
Tam |
Leptospira in community and privately-owned cats in Hong Kong: serology and urinary shedding |
| ISCAID-O-14 |
17.30-17.45 |
Lutz |
Plasma procalcitonin and C-reactive protein in dogs with suspected bacterial pneumonia or non-bacterial pulmonary diseases |
| ISCAID-O-15 |
17.45-18.00 |
Scahill |
Antimicrobial use in 6270 European dogs: a retrospective cohort study (2019-2021) |
| ESVONC – European Society of Veterinary Oncology |
| Friday 22 September |
| ESVONC-O-1 |
14.25-14.40 |
Žagar |
Biologic behaviour of canine preputial, scrotal and vulvar cutaneous mast cell tumours: a single-centre retrospective analysis of 102 dogs (2002-2022) |
| ESVONC-O-2 |
14.40-14.55 |
Loddo |
Canine large granular lymphocyte (LGL) lymphoma: A retrospective study of 42 cases. |
| ESVONC-O-3 |
14.55-15.10 |
Lecot |
Treatment and outcome of myeloma-related disorders in cats: a multicentric retrospective study of 50 cases |
| ESVONC-O-4 |
15.10-15.25 |
Chalfon |
Flow cytometry for detection and quantification of nodal metastasis in dogs with treatment-naïve firstly occurring cutaneous mast cell tumour |
| ESVONC-O-5 |
15.25-15.40 |
Ubiali |
Evaluation of programmed death-ligand 1 expression in canine lymphomas using flow cytometry |
| ESVONC-O-6 |
15.40-15.55 |
Lyseight |
Flow cytometry expression in canine T cell lymphoma; presentation, prognosis and response to lomustine-based protocols used in the naïve setting |
| ESVONC-O-7 |
16.30-16.45 |
Agnoli |
Peripheral blood and bone marrow involvement do not worsen outcome in 50 dogs with nodal peripheral t-cell lymphoma receiving alkylating-rich chemotherapy |
| ESVONC-O-8 |
16.45-17.00 |
Hawkes |
Comparison of first-line CHOP-19 and CHOP-25 in the treatment of canine aggressive peripheral nodal B-cell lymphomas: a European multicentric retrospective cohort study |
| ESVONC-O-9 |
17.00-17.15 |
Treggiari |
Incidence of gastrointestinal toxicity and treatment outcome in dogs with multicentric lymphoma receiving doxorubicin or epirubicin as part of a multi-agent chemotherapy protocol |
| ESVONC-O-10 |
17.15-17.30 |
Scheemaeker |
Optimization of radioactive iodine uptake in canine thyroid carcinomas using recombinant human thyroid stimulating hormone |
| ESVONC-O-11 |
17.30-17.45 |
Guerra |
Serum lactate dehydrogenase acts as a potential prognostic biomarker of canine appendicular osteosarcoma |
| ESVONC-O-12 |
17.45-18.00 |
Capuano |
Investigation and description of circulating MicroRNAs in healthy and T-cell lymphoma-bearing dogs: a prospective, two-arm study |
| ESVE – European Society of Veterinary Endocrinology |
| Saturday 23 September |
| ESVE-O-1 |
08.00-08.15 |
Foale |
Induction of hepatic insulin production using AAV gene therapy in naturally-occuring canine diabetes mellitus; a potential future treatment? |
| ESVE-O-2 |
08.15-08.30 |
Tardo |
Effect of two diets on glycemic variability and glycemic control assessed by flash glucose monitoring system in diabetic dogs |
| ESVE-O-3 |
08.30-08.45 |
Niessen |
Efficacy and safety of once daily oral sodium-glucose co-transporter-2-inhibitor velagliflozin compared to twice daily insulin injection therapy in diabetic cats |
| ESVE-O-4 |
09.00-09.15 |
Miceli |
Increased insulin-like growth factor 1 concentrations in a population of non-diabetic cats with overweight/obesity |
| ESVE-O-5 |
09.15-09.30 |
Norman |
A genome-wide association study investigating the genetic basis of hyperthyroidism in domestic cats. |
| ESVE-O-6 |
09.30-09.45 |
Menzel |
Effect of duration of hyperthyroidism and degree of thyroid pathology on recovery of pituitary-thyroid axis and creatinine concentration in radioiodine-treated cats followed up over a 1-year period |
| ESVE-O-7 |
09.45-10.00 |
Williams |
Survival times of radioiodine treated hyperthyroid cats with and without iatrogenic hypothyroidism and investigation of effect of levothyroxine supplementation on survival time |
| ESVE-O-8 |
10.00-10.15 |
Travail |
Serum parathyroid hormone concentration as a predictor of post-operative hypocalcemia in dogs diagnosed of primary hyperparathyroidism and treated with parathyroidectomy |
| ESVE-O-9 |
10.15-10.30 |
van den Berg |
Metabolite profiling in canine pheochromocytomas, cortisol-secreting adrenocortical tumors, and normal adrenals |
| ESVE-O-10 |
11.20-11.35 |
Golinelli |
Addition of cabergoline to trilostane treatment for dogs with pituitary-dependent hypercortisolism |
| ESVE-O-11 |
11.35-11.50 |
Jankovic |
Electrophoretic patterns of proteinuria in dogs with Cushing’s syndrome and glomerular disease |
| ESVE-O-12 |
11.50-12.05 |
Fracassi |
Comparison of urinary cortisol and basal serum cortisol as a screening test for hypoadrenocorticism in dogs |
| ESVE-O-13 |
12.05-12.20 |
Roberts |
Clinical findings, treatment and outcomes in cats with spontaneous hypoadrenocorticism: 41 cases |
| ESVE-O-14 |
12.20-12.35 |
Watson |
Identification of somatic mutations in feline adrenal tumours causing primary hyperaldosteronism |
| ESVE-O-15 |
12.35-12.50 |
Chamagne |
Evaluation of serum steroid profile in healthy cats, cats with chronic kidney disease and cats with primary hyperaldosteronism |
| ESVCN – European Society of Veterinary Comparative Nutrition |
| Saturday 23 September |
| ESVCN-O-1 |
15.10-15.25 |
Dobenecker |
Short-term oral intake of inorganic phosphate additives causes an increase of FGF23 in cats and dogs |
| ESVCN-O-2 |
15.25-15.40 |
Blanchard |
Beneficial response to a very low-carbohydrate home-cooked diet in dogs with refractory chronic enteropathy: pilot study of 25 cases |
| ESVCN-O-3 |
15.40-15.55 |
Pignataro |
Follow-up in 167 homemade diets for maintenance and pathologic conditions in dog |
| ESVCN-O-4 |
15.55-16.10 |
Bela |
Effects of Lactobacillus reuteri NBF 2 DSM 32264 supplementation on healthy Certosino cat performance |
